- ISIN
- US8006771062
- CUSIP
- 800677106
- Delisting Date
- Jun 24, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 6, 2000
Highlights
- Market Cap
- $30.66M
- Enterprise Value
- $22.40M
- EPS (TTM)
- -$0.36
- Total Revenue (TTM)
- $34.56M
- Gross Profit (TTM)
- $25.51M
- EBITDA (TTM)
- -$106.29M
- Year Range
- $0.06 - $0.77
- Target Price
- $7.25
- ROA (TTM)
- -205.67%
- ROE (TTM)
- 650.65%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SGMO Performance Chart
Loading charts...
Compare this symbol against anything
Returns By Period
Sangamo Therapeutics, Inc.
- 1D
- —
- 1M
- —
- 6M
- —
- YTD
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
SGMO Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 27.50% | -19.27% | -42.89% | -51.72% | 82.63% | -66.01% | 0.00% | -82.38% | |||||
| 2025 | 20.59% | -17.07% | -35.71% | 17.73% | -39.77% | 16.41% | -0.78% | -3.18% | 29.50% | -11.20% | -22.91% | -8.89% | -58.82% |
| 2024 | -15.88% | 153.83% | -42.22% | -23.17% | 9.61% | -36.52% | 118.42% | 8.36% | 2.13% | 96.28% | 32.94% | -54.87% | 87.74% |
| 2023 | 11.15% | -12.61% | -42.30% | -16.48% | -23.81% | 16.07% | 1.15% | -26.29% | -38.12% | 5.07% | -31.77% | 26.35% | -82.70% |
| 2022 | -19.60% | -2.99% | -0.68% | -28.57% | -12.05% | 13.42% | 3.62% | 25.87% | -9.26% | -10.41% | -16.63% | -14.21% | -58.13% |
| 2021 | -12.46% | -15.89% | 9.05% | -5.99% | -8.49% | 11.04% | -19.97% | 3.44% | -9.08% | -9.88% | 2.09% | -9.53% | -51.94% |
Benchmark Metrics
Sangamo Therapeutics, Inc. has an annualized alpha of 9.48%, beta of 1.55, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since April 06, 2000.
- This stock participated in 218.60% of S&P 500 Index downside but only 207.19% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 9.48%
- Beta
- 1.55
- R²
- 0.11
- Upside Capture
- 207.19%
- Downside Capture
- 218.60%
Return for Risk
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SGMO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.25 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.00 | — |
| Martin ratioReturn relative to average drawdown | — | 8.49 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sangamo Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sangamo Therapeutics, Inc. was 99.85%, occurring on Jun 23, 2026. The portfolio has not yet recovered.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.85%Jun 2026 | 25y 9mo | — | 25y 11moSep 2000 - now | — |
-56.01%May 2000 | 1mo 24d | 12d | 2mo 6dApr 2000 - Jun 2000 | Dot-com crash2000–2002 |
-41.46%Aug 2000 | 7d | 28d | 1mo 5dJul 2000 - Aug 2000 | Dot-com crash2000–2002 |
-20.03%Jun 2000 | 3d | 4d | 7dJun 2000 - Jun 2000 | Dot-com crash2000–2002 |
-15.18%Jul 2000 | 1d | 5d | 6dJul 2000 - Jul 2000 | Dot-com crash2000–2002 |
Drawdown Indicators
| SGMO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -1.58% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.70% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 2.14% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sangamo Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sangamo Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SGMO relative to other companies in the Biotechnology industry. Currently, SGMO has a P/S ratio of 0.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SGMO
Add Sangamo Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SGMO